FEATURED
COVID 19 Articles
Federal Reserve is likely to hold interest rates steady in October. Here’s what that means for consumers
The Federal Reserve is expected to keep interest rates unchanged at its October meeting despite rising inflation driven by higher energy costs and their impact on household budgets.
Midterm elections: How affordability and the economy could affect voters’ decisions
Rising costs for everyday goods like gas and groceries are dominating midterm election discussions, with affordability emerging as the central issue affecting voters’ decisions at the ballot box.
Robot factories and hypersonic missiles: JPMorgan Chase’s first $5 billion of defense investments
JPMorgan Chase deployed $5 billion into defense and manufacturing startups in the first year of its security initiative, exceeding expectations and signaling potential program expansion beyond the initial $10 billion commitment.
Civil servant who juggled five jobs ‘wasn’t thinking straight’
A civil servant accused of holding five simultaneous public sector jobs denies fraud, claiming he was panicked about job security and not thinking clearly when he failed to disclose his employment status.
Trending COVID 19 News
AARP to Congress: ‘We strongly object to fast-tracking Social Security changes’
AARP opposes a bipartisan Senate proposal to fast-track Social Security overhaul legislation, arguing such changes require regular congressional order rather than expedited procedures.
TSMC, the world’s largest contract chipmaker, reports 68% surge in June revenue
Taiwan Semiconductor Manufacturing Co. reported a 67.9% year-on-year increase in June revenue, with first-half 2026 sales reaching 2.4 trillion new Taiwan dollars.
IBM lowers full-year forecast after earnings warning
IBM lowered its 2026 revenue growth forecast to 4-5% in constant currency, down from prior guidance exceeding 5%, after reporting earnings that missed analyst expectations on Wednesday.
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly announced it will seek regulatory approval for its obesity drug retatrutide in the first quarter of 2027 after succeeding in two additional late-stage clinical trials.
American Airlines stock tumbles 8% as fuel spike further postpones turnaround
American Airlines cut its 2026 earnings forecast Thursday due to rising fuel costs, with stock falling 8% as higher fares prove insufficient to offset the expense spike.
Comcast earnings highlight NBCUniversal strength ahead of planned split
Comcast reported strong second-quarter results, with NBCUniversal’s Peacock achieving profitability for the first time, though the broadband business continued losing customers ahead of a planned company split.
Albertsons stock plunges as it says weaker grocery spending will cut into sales and earnings
Albertsons shares dropped more than 20% after the grocer cut its fiscal 2026 earnings outlook, citing weakened consumer spending and softer demand in its core grocery business.
Oil prices tumble as U.S.-Iran tensions show signs of easing
Crude oil prices fell sharply on Monday as geopolitical tensions between the U.S. and Iran showed signs of easing, with Brent crude down 6% to $90.93 per barrel.
Gold edges higher as softer dollar offsets easing geopolitical tensions
Gold prices advanced on Monday as a softer dollar bolstered demand, though investors weighed easing Middle East tensions against anticipation of the Federal Reserve’s upcoming policy decision.
Five market themes investors will be watching this week
Financial markets face a critical week with Federal Reserve decisions, major technology earnings from Microsoft, Meta, Apple and Amazon, and economic data expected to influence global asset trading.
VW H1 operating profit falls 11.6% on US ID.4 exit, China slump
Volkswagen’s first-half operating profit fell 11.6% to €5.93bn, driven by US ID.4 production exit costs and a 31.6% decline in China amid challenging market conditions.
Morning Bid: China chip champ
Chinese chipmaker CXMT surged nearly 500% in its Shanghai debut, becoming China’s most valuable stock. The $8.6 billion IPO reflects growing focus on chip sector amid geopolitical tensions.